Kevin J. Ballinger Sells 28,864 Shares of Boston Scientific Co. (BSX) Stock
Boston Scientific Co. (NYSE:BSX) EVP Kevin J. Ballinger sold 28,864 shares of Boston Scientific stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $26.14, for a total transaction of $754,504.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Boston Scientific Co. (NYSE:BSX) traded up 0.77% on Thursday, hitting $26.14. 5,673,609 shares of the stock were exchanged. Boston Scientific Co. has a 52 week low of $19.67 and a 52 week high of $26.76. The company has a market cap of $35.80 billion, a PE ratio of 83.78 and a beta of 1.06. The company’s 50-day moving average is $25.48 and its 200-day moving average is $23.66.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, April 27th. The medical equipment provider reported $0.29 EPS for the quarter, missing the Zacks’ consensus estimate of $0.30 by $0.01. Boston Scientific had a return on equity of 23.70% and a net margin of 4.14%. The business had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.08 billion. During the same quarter in the previous year, the business posted $0.28 earnings per share. The company’s revenue was up 10.0% compared to the same quarter last year. On average, analysts predict that Boston Scientific Co. will post $1.25 earnings per share for the current year.
WARNING: “Kevin J. Ballinger Sells 28,864 Shares of Boston Scientific Co. (BSX) Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/05/18/kevin-j-ballinger-sells-28864-shares-of-boston-scientific-co-bsx-stock.html.
Large investors have recently bought and sold shares of the company. FMR LLC increased its stake in Boston Scientific by 7.6% in the first quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock worth $4,593,698,000 after buying an additional 13,105,596 shares during the period. BlackRock Inc. increased its stake in Boston Scientific by 2,181.6% in the first quarter. BlackRock Inc. now owns 95,744,545 shares of the medical equipment provider’s stock worth $2,381,169,000 after buying an additional 91,548,235 shares during the period. Vanguard Group Inc. increased its stake in Boston Scientific by 4.0% in the first quarter. Vanguard Group Inc. now owns 91,134,744 shares of the medical equipment provider’s stock worth $2,266,521,000 after buying an additional 3,503,965 shares during the period. Capital World Investors increased its stake in Boston Scientific by 2.9% in the third quarter. Capital World Investors now owns 84,331,654 shares of the medical equipment provider’s stock worth $2,007,093,000 after buying an additional 2,391,520 shares during the period. Finally, State Street Corp increased its stake in Boston Scientific by 3.2% in the fourth quarter. State Street Corp now owns 61,481,035 shares of the medical equipment provider’s stock worth $1,329,837,000 after buying an additional 1,907,944 shares during the period. 91.70% of the stock is owned by institutional investors.
A number of equities analysts recently weighed in on BSX shares. Oppenheimer Holdings Inc. set a $27.00 price objective on shares of Boston Scientific and gave the company a “hold” rating in a research report on Friday, April 28th. Goldman Sachs Group Inc started coverage on shares of Boston Scientific in a research report on Tuesday. They issued a “neutral” rating and a $28.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price objective (up from $29.00) on shares of Boston Scientific in a research report on Thursday, April 27th. Guggenheim reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, April 12th. Finally, Stifel Nicolaus lifted their price objective on shares of Boston Scientific from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, April 28th. Six equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. Boston Scientific currently has an average rating of “Buy” and a consensus price target of $27.83.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Co. and related companies with MarketBeat.com's FREE daily email newsletter.